European regulator says evidence shows no thyroid cancer link to GLP-1s
Current evidence doesn’t support a link between GLP-1 receptor agonists and thyroid cancer, Europe’s drug regulator announced Friday following safety concerns that have been raised for the popular weight loss and diabetes drugs.
The European Medicines Agency flagged a thyroid cancer safety signal earlier this year over a 2022 study suggesting a potential increased risk in patients with type 2 diabetes. After reviewing data from publications, observational studies and drugmakers (including clinical and post-marketing data), the EMA’s safety committee has determined that “no updates to the product information are warranted based on the available data.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.